Related references
Note: Only part of the references are listed.Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survival
Naseema Gangat et al.
AMERICAN JOURNAL OF HEMATOLOGY (2023)
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study
Paola Guglielmelli et al.
BLOOD ADVANCES (2022)
Momelotinib for myelofibrosis: 12-year survival data and retrospective comparison to ruxolitinib
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2022)
Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management
Ayalew Tefferi
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis
A. Pardanani et al.
LEUKEMIA (2018)
MIPSS70+Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis
Ayalew Tefferi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Momelotinib therapy for myelofibrosis: a 7-year follow-up
Ayalew Tefferi et al.
BLOOD CANCER JOURNAL (2018)
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
Claire N. Harrison et al.
LANCET HAEMATOLOGY (2018)
Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naive Patients With Myelofibrosis
Ruben A. Mesa et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib
Keyur P. Patel et al.
BLOOD (2015)
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
Alessandro M. Vannucchi et al.
HAEMATOLOGICA (2015)
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
Alessandro M. Vannucchi et al.
HAEMATOLOGICA (2015)
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis A Randomized Clinical Trial
Animesh Pardanani et al.
JAMA ONCOLOGY (2015)
Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis
A. Pardananil et al.
LEUKEMIA (2015)
Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study
Paola Guglielmelli et al.
BLOOD (2014)
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
Ayalew Tefferi et al.
BLOOD (2013)
Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
A. Pardanani et al.
LEUKEMIA (2013)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Claire Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
Naseema Gangat et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
Animesh Pardanani et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis
Ayalew Tefferi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis.
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Share Paper
